|Titre :||Synthetic cathinones and their potential interactions with prescription drugs (2019)|
|Auteurs :||R. R. CONTRUCCI ; T. M. BRUNT ; F. INAN ; E. J. F. FRANSSEN ; L. HONDEBRINK|
|Type de document :||Article : Périodique|
|Dans :||Therapeutic Drug Monitoring (Online first 16/08/2019, 2019)|
|Article en page(s) :||doi: 10.1097/FTD.0000000000000682|
|Discipline :||PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)|
Thésaurus TOXIBASECATHINONES ; DROGUES DE SYNTHESE ; MEDICAMENTS ; INTERACTION CHIMIQUE ; POLYCONSOMMATION ; ANTIDEPRESSEURS ; PHARMACOCINETIQUE ; MECANISME D'ACTION ; BUPROPION ; NEUROTRANSMETTEURS
Purpose: Substance use disorder often coexists with other psychiatric disorders, resulting in the simultaneous use of recreational and prescription drugs. The authors aimed to identify potential pharmacokinetic and pharmacodynamic interactions between new psychoactive substances of the cathinone class and specific prescription drugs.
Methods: The authors performed a systematic literature review on interactions between synthetic cathinones (mephedrone, methylone, methylenedioxypyrovalerone and alpha-pyrrolidinopentiophenone) and antidepressants (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine), ADHD medications (atomoxetine, dexamphetamine, methylphenidate, modafinil) or HIV medications.
Results: Although no pharmacokinetic interactions have been reported in previous literatures, such interactions are likely to occur. Metabolic pathways of cathinones, antidepressants, and ADHD medications have been shown to overlap, including metabolism via cytochrome P450 enzymes and their inhibition. Consistent with this finding, interactions of bupropion (a cathinone) with antidepressants and ADHD medications have been found to increase their serum concentrations and half-lives. Additionally, limited pharmacodynamic interactions have been reported. However, as cathinones, antidepressants, and ADHD medications have been reported to increase the extracellular monoamine concentration by affecting reuptake transporters, interactions among these compounds are likely. Presumably, even higher monoamine concentrations could be observed when cathinones are combined with prescription drugs with a similar mode of action, as has been reported in animals exposed to duloxetine and bupropion. HIV medications have a different mode of action; thus, they have been reported to be less likely to have pharmacodynamic interactions with cathinones.
Conclusion: Clinicians should be aware of possible interactions between synthetic cathinones and prescription drugs, which may increase the risk of drug toxicity or reduce the therapeutic efficacy of the drugs. Qualitative drug screening for cathinones using mass spectrometry methods may aid the early detection of these agents.
|Domaine :||Autres substances / Other substances ; Drogues illicites / Illicit drugs|
|Sous-type de document :||Revue de la littérature / Literature review|
|Refs biblio. :||66|
|Affiliation :||Dutch Poisons Information Center, University Medical Center Utrecht, Utrecht University, the Netherlands|